Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levocetirizine
Drug ID BADD_D01272
Description Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine].[L7694] Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Indications and Usage Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria.[L7694] It is also used over the counter for a variety of mild allergy symptoms.[A181748]
Marketing Status approved
ATC Code R06AE09
DrugBank ID DB06282
KEGG ID D07402
MeSH ID C472067
PubChem ID 1549000
TTD Drug ID D0M8PW
NDC Product Code Not Available
UNII 6U5EA9RT2O
Synonyms levocetirizine | levocetrizine | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- | (2-(4-((R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid | levocetirizine hydrochloride | Xusal | levocetirizine dihydrochloride | (2-(4-((R)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride | cetirizine (R)-form dihydrochloride | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride | Xyzal | UCB-28556
Chemical Information
Molecular Formula C21H25ClN2O3
CAS Registry Number 130018-77-8
SMILES C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abortion spontaneous18.01.04.0010.000194%Not Available
Aggression19.05.01.001--Not Available
Agitation19.06.02.001; 17.02.05.012--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Angina pectoris24.04.04.002; 02.02.02.0020.000130%
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.0020.000130%
Arrhythmia02.03.02.0010.000130%Not Available
Asthenia08.01.01.0010.000194%Not Available
Asthma22.03.01.002; 10.01.03.0100.000130%Not Available
Atrial fibrillation02.03.03.0020.000130%
Blindness06.02.10.003; 17.17.01.0030.000130%Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.0020.000194%Not Available
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.000194%Not Available
Choking sensation22.12.03.004; 19.01.02.0020.000130%Not Available
Cholestasis09.01.01.001--Not Available
Circulatory collapse24.06.02.0010.000130%Not Available
Condition aggravated08.01.03.0040.000350%Not Available
Constipation07.02.02.001--
Cough22.02.03.0010.000350%
Crying19.04.02.002; 17.02.05.013; 12.02.11.001; 08.01.03.0050.000453%Not Available
Decreased activity19.11.01.002; 08.01.01.0060.000194%Not Available
Delirium19.13.02.0010.000194%
Depressed mood19.15.02.0010.000194%Not Available
Depression19.15.01.0010.000674%
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.0020.000194%Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages